After suffering sharp losses in the first half of the year, biopharma-focused hedge funds continued to bounce back last month. Several of them are now either in the black, at breakeven, or close to breakeven heading into the final month of the year.
(Lauryn Ishak/Bloomberg)
After suffering sharp losses in the first half of the year, biopharma-focused hedge funds continued to bounce back last month. Several of them are now either in the black, at breakeven, or close to breakeven heading into the final month of the year.
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.
